Clinical Trials Logo

Chemoembolization, Therapeutic clinical trials

View clinical trials related to Chemoembolization, Therapeutic.

Filter by:
  • None
  • Page 1

NCT ID: NCT03283956 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma Non-resectable

Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan

SERENADE-T
Start date: September 13, 2017
Phase: N/A
Study type: Observational

To evaluate efficacy and safety profile of DC bead® TACE in patients with hepatocellular carcinoma in Taiwan.

NCT ID: NCT02764801 Completed - Clinical trials for Hepatocellular Carcinoma

Contrast-enhanced Ultrasound Evaluation of Chemoembolization

Start date: April 2016
Phase: Phase 3
Study type: Interventional

The primary objective of this trial is to evaluate the sensitivity and specificity of 2D and 4D contrast enhanced ultrasound for monitoring transarterial chemoembolization (TACE) response 1-2 weeks and 1 month post treatment as an alternative to contrast-enhanced magnetic resonance (MRI) or computed tomography (CT) imaging

NCT ID: NCT02435953 Recruiting - Clinical trials for Hepatocellular Carcinoma

TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma

Start date: April 2015
Phase: Phase 4
Study type: Interventional

The current standard treatment for intermediate-stage HCC (BCLC stage B) is transcatheter arterial chemoembolization (TACE) alone.The combination of TACE with RFA has also reported to be an effective treatment for HCC. Some prospective studies have shown TACE combined RFA to have better efficacy than any of them alone for early stage HCC (single tuomor ≤5 cm). However, to the investigators' knowledge, there have not been any prospective studies to assess whether TACE combined sequentially with RFA is more effective than TACE alone for the treatment of intermediate-stage HCC. The investigators hypothesized that the combination of TACE and RFA might result in better patient survival than TACE alone. Thus, the purpose of this study was to prospectively compare the effects of sequential TACE-RFA with TACE alone for the treatment of intermediate-stage HCC. Intermediate-stage HCC in this study was defined as 2-3 intrahepatic lessions, largest tumor size 3-7 cm or 4-10 intrahepatic lessions, largest tumor size ≤7 cm; ECOG-PS 0;Child-pugh A or B;no tumor thrombus or extrahepatic metastases.